Substituted analogues of GV150526 as potent glycine binding site antagonists in animal models of cerebral ischemia

Journal of Medicinal Chemistry

Volumn 42, Issue 18, 1999, Pages 3486-3493

  Di Fabio, Romano ^a   Conti, Nadia ^a   De Magistris, Elisabetta ^a   Feriani, Aldo ^a   Provera, Stefano ^a   Sabbatini, Fabio Maria ^a   Reggiani, Angelo ^a   Rovatti, Luca ^a   Barnaby, Robert J ^a  

^a GSK   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ANALOG; GAVESTINEL; GLYCINE RECEPTOR ANTAGONIST; GV 228869; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN ISCHEMIA; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; NEUROPROTECTION; NONHUMAN; RAT; STRUCTURE ANALYSIS;

ANIMALS; ANTICONVULSANTS; BINDING SITES; BRAIN ISCHEMIA; CEREBRAL INFARCTION; DISEASE MODELS, ANIMAL; GLYCINE; GLYCINE AGENTS; INDOLES; MICE; MOLECULAR STRUCTURE; NEUROPROTECTIVE AGENTS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLYCINE; RECEPTORS, N-METHYL-D-ASPARTATE; UREA;

EID: 0033539164     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980576n     Document Type: Article

References (51)

1. For a recent review on several neuroprotective approaches potentially useful after stroke onset, see: Zivin, J. A. Neuroprotective Therapies in Stroke. Drugs 1997, 54, 83-89.
2. Collingridge, G. L., Watkins, J. C., Eds. The NMDA Receptor, 2nd ed.; IRL Press: Oxford, England, 1994.
3. (a) Graham, S. H.; Chen, J.; Sharp, F. R.; Simon, P. R. Limiting Ischemic Injury by Inhibition of Excitatory Amino Acids Release. J. Cerebr. Blood Flow Metab. 1993, 13, 88-97.
4. (b) McCullogh, J. Excitatory Amino Acid Antagonists and Their Potential for the Treatment of Ischaemic Brain Damage in Man. Br. J. Clin. Pharmacol. 1992, 34, 106-114.
5. (c) Choi, D. W.; Rothman, S. M. The Role of Glutamate Neurotoxicity in Hypoxic-Ischemic Neuronal Death. Annu. Rev. Pharmacol. Toxicol. 1991, 31, 171-182.
6. (d) Choi, D. W. Methods for Antagonizing Glutamate Neurotoxicity. Cerebrovasc. Brain Metab. Rev. 1990, 2, 105-147.
7. (e) Meldrum, B.; Garthwaite, J. Excitatory Amino Acid Neurotoxicity and Neurodegenerative Diseases. Trends Pharmacol. 1990, 11, 379-387.
8. (f) Choi, D. W. Cerebral Hypoxia: Some New Approaches and Unaswered Questions. J. Neurosci. 1990, 10, 2493-2501.
9. (g) Meldrum, B. Protection Against Ischaemic Neuronal Damage by Drugs Acting on Excitatory Neurotransmission. Cerebrovasc. Brain Metab. Rev. 1990, 2, 27-57.
10. Bath, P. Stroke Therapy: Advances and Commercial Opportunities, 1st ed.; CONNECT Pharma Ltd.: Oxford, England, 1995.
11. (a) Johnson, J. W.; Asher, P. Glycine Potentiates the NMDA Receptor Response in Cultured Brain Mouse Neurones. Nature 1987, 325, 529-531.
12. (b) Kleckner, N. W.; Dingledine, R. Requirements for Glycine in Activation of NMDA Receptor Expressed in Xenopus Oocytes. Science 1988, 241, 835-837.
13. Reviews: (c) Huettner, J. E. Competitive Antagonism of Glycine at hte N-Methyl-D-Aspartate (NMDA) Receptor. Biochem. Pharmacol. 1991, 41, 9-16.
14. (d) Thomson, A. M. Glycine is a Coagonist at the NMDA Receptor/Ion Channel Complex. Prog. Neurobiol. 1990, 35, 53-74. Wong, E. H. F.; Kemp, J. A. Site for Antagonism on the N-methyl-D-aspartate Receptor Channel Complex. Annu. Rev. Pharmacol. Toxicol. 1991, 31, 401-425.
15. (d) Thomson, A. M. Glycine is a Coagonist at the NMDA Receptor/Ion Channel Complex. Prog. Neurobiol. 1990, 35, 53-74. Wong, E. H. F.; Kemp, J. A. Site for Antagonism on the N-methyl-D-aspartate Receptor Channel Complex. Annu. Rev. Pharmacol. Toxicol. 1991, 31, 401-425.
16. Reviews: (a) Palfreyman, M. G.; Baron, M. B. Noncompetitive NMDA Antagonists Acting at the Glycine Site. In Excitatory Amino Acid Antagonists; Meldrum, B., Ed.; Blackwell: Oxford, England, 1991; Chapter 6, pp 101-129.
17. (b) Carter, A. J. Glycine Antagonists: Regulation of the NMDA Receptor-Complex by the Strychnine -insensitive Glycine Site. Drugs Future 1992, 17, 595-613.
18. (c) Kemp, J. A.; Leeson, P. D. The Glycine Site of the NMDA Receptor - Five Years On. TiPS 1993, 14, 20-25.
19. (d) Leeson, P. D.; Iversen, L. L. The Glycine Site on the NMDA Receptor: Structure-Activity Relationships and Therapeutic Potential. J. Med. Chem. 1994, 37, 4053-4067.
20. (e) Iversen, L. L.; Kemp, J. A. Non Competitive NMDA Antagonists as Drugs. In The NMDA Receptor, 2nd ed.; Collingridge, G. L., Watkins, J. C., Eds.; IRL Press: Oxford, England, 1994; Chapter 20, pp 469-486.
21. (f) Di Fabio, R.; Gaviraghi, G.; Reggiani, A. The Strychnine-insensitive Glycine Binding Site and the NMDA Receptor. Chim. l'Indust. 1996, 78, 283-289.
22. (a) Bielemberg, G. W.; Beck, T. The Effect of Dizocilpine (MK-801), Phenylcyclidine, and Nemodipine on Infart Size 48 h After Middle Cerebral Artery Occlusion in the Rat. Brain Res. 1991, 552, 338-342.
23. (b) Park, C. K.; Nehls, D. G.; Graham, D. I.; Teasdale, G. M.; McCullogh, J. The Glutamate Antagonist MK-801 Reduced Focal Ischemic Brain Damage in the Rat. Ann. Neurol. 1988, 24, 543-551.
24. (c) Warner, D. S.; Martin, H.; Ludwig, P.; McAllister, A.; Keana, J. F. W.; Weber, E. In Vivo Models of Cerebral Ischemia: Effects on Parenterally Administered NMDA Receptor Glycine Site Antagonists. J. Cerebr. Blood Flow Metab. 1995, 15, 188-196.
25. Tamura, A.; Graham, D. I.; McCullogh, J.; Teasdale, G. M. Focal Cerebral lschaemia in the Rat: I. Description of techniques and Early Neuropathological Consequences Following Middle Cerebral Artery Occlusion. J. Cerebr. Blood Flow Metab. 1981, 1, 53-60.
26. (a) Di Fabio, R.; Cugola, A.; Donati, D.; Feriani, A.; Gaviraghi, G.; Ratti, E.; Trist, D. G.; Reggiani, A. Identification and Pharmacological Characterization of GV150526A, a Novel Glycine Antagonist as a Potent Neuroprotective Agent. Drugs Future 1998, 23, 1, 61-69.
27. (b) Di Fabio, R.; Capelli, A. M.; Conti, N.; Cugola, A.; Donati, D.; Feriani, A.; Gastaldi, P.; Gaviraghi, G.; Hewkin, C. T.; Micheli, F.; Missio, A.; Mugnaini, M.; Pecunioso, A.; Quaglia, A. M.; Ratti, E.; Rossi, L.; Tedesco, G.; Trist, D. G.; Reggiani, A. Substituted Indole-2-carboxylates as in Vivo Potent Antagonists Acting at the Strychnine-Insensitive Glycine Binding Site. J. Med. Chem. 1997, 40, 841-850.
28. (c) Micheli, F.; Di Fabio, R.; Capelli, A. M.; Cugola, A.; Curcuruto, O.; Feriani, A.; Gastaldi, P.; Gaviraghi, G.; Marchioro, C.; Orlandi, A.; Pozzan, A.; Quaglia, A. M.; Reggiani, A.; van Amsterdam, F. Cycloalkyl Indole-2-Carboxylates as Useful Tools for Mapping the "North-Eastern" Region of the Glycine Binding Site Associated with the NMDA Receptor. Arch. Pharm. Pharm. Med. Chem. 1999, 332, 73-80.
29. (d) The Glycine Antagonist GV150526 Protects Somatosensory Evoked Potentials and Reduces the Infarct Area in the MCAo Model of Focal Ischaemia in the Rat. Exp. Neurol. 1997, 145, 425-433.
30. (e) Di Fabio, R.; Cugola, A.; Donati, D.; Feriani, A.; Gaviraghi, G.; Ratti, E.; Trist, D. Novel Substituted Indole-2-Carboxylates as Potent Glycine Antagonists. ACS Book of Abstracts; 211th ACS National Meeting, New Orleans, LA, March 24-28, 1996; Abstract 107.
31. (f) Bordi, F.; Pietra, C.; Ziviani, L.; Reggiani, A. Neuroprotection of GV150526A. Comparison with Reference Compounds. Stroke 1996, 27, 26.
32. (g) Gaviraghi, G.; Cugola, A.; Giacobbe, S. Eur. Patent 0568136 A1, 1993.
33. (a) Meldrum, B. S.; Chapman, A. G. Competitive NMDA Antagonists as Drug. In The NMDA Receptor, 2nd ed.; Collingridge, G. L., Watkins, J. C., Eds.; IRL Press: Oxford, England, 1994; Chapter 19, pp 457-468.
34. (b) Iversen, L. L.; Kemp, J. A. Non competitive NMDA Antagonists as Drug. In The NMDA Receptor, 2nd ed.; Collingridge, G. L., Watkins, J. C., Eds.; IRL Press: Oxford, England, 1994; Chapter 20, pp 469-486.
35. Mukaiyama, T.; Matsueda, R.; Suzuky, M. Peptide Synthesis via the Oxidation-Reduction Condensation by Use of 2,2′-Dipyridyl disulfide as an Oxidant. Tetrahedron Lett. 1970, 22, 1901-1904.
36. Di Fabio, R.; Summa, V.; Rossi, T.; Synthesis of Amides: An Efficient and Chemoselective Method for the Preparation of β-lactam Derivatives Related to HLE Inhibitors. Tetrahedron 1993, 49, 2300-2306.
37. Kishimoto, H.; Simon, J. R.; Aprison, M. H. Determination of the Equilibrium Dissociation Constants at a Number of Glycine Binding Sites in Several Areas of the Rat Central Nervous System, Using a Na-Independent System. J. Neurochem. 1981, 37, 1015-1024.
38. Kloog, Y.; Haring, R.; Sokolovsky, M. Kinetic Characterization of the Phenylcyclidine-N-Methyl-D-Aspartate Receptor Interaction: Evidence for Steric Blockade of the Channel. Biochemistry-US 1988, 27, 843-848.
39. Ratti, E.; Tacconi, S.; Graziani, F.; Gaviraghi, G. Requirement of the Glycine for the GlutamateActivity at the NMDA Receptor Site. Eur. J. Pharmacol. 1990, 183, 1665.
40. van Amsterdam, F. Th. M.; Giberti, A.; Mugnaini, M.; Ratti, E. 3-[(±)-2-Carboxypiperazin-4-yl]propyl-1-Phosphonic Acid Recognizes Two N-Methyl-D-Aspartate Binding Sites in Rat Cerebral Cortex Membranes. J. Neurochem. 1992, 59, 1850-1855.
41. 3H]-a-Amino-3-Hydroxy-5-Methyl-Isoxazole-4-Propionic Acid (AMPA) to Rat Cortex Membranes Reveals Two Sites or Affinity States. J. Recept. Res. 1991, 11, 727-741.
42. 3H]Kainate Binding Sites with Different Molecular Target Sizes in Rat Cortex. Neurosci. Lett. 1986, 65, 47-52.
43. Chiamulera, C.; Costa, S.; Reggiani, A. Effect of NMDA and Strychnine-Insensitive Glycine Site Antagonists on NMDA-Mediated Convulsions and Learning. Psycopharmacology 1990, 112, 551-552.
44. Rowley, M.; Kulagowsky, J. J.; Watt, A. P.; Rathbone, D.; Stevenson, G. I.; Carling, R. W.; Baker, R.; Marshall, G. R.; Kemp, J. A.; Foster, A. C.; Grimwood, S.; Hargreaves, R.; Hurley, C.; Saywell, K. L.; Trickleback, M. D.; Leeson, P. D. Effect of Plasma Protein Binding on in vivo Activity and Brain Penetration of Glycine/NMDA Receptor Antagonists. J. Med. Chem. 1997, 40, 4053-4068.
45. Domenici, E.; Bertucci, E.; Salvatori, P.; Motellier, S.; Wainer, I. W. Immobilized Serum Albumin: Rapid HPLC Probe of Steroselective Protein-Binding Interactions. Chirality 1990, 2, 263-268.
46. Pacifici, G. M.; Viani, A. Methods of Determining Plasma and Tissue Protein Binding: Pharmacokinetic Consequences. Clin. Pharmacokinet. 1992, 23, 449-468.
47. (a) Keana, J. F. W.; Kher, S. M.; Sui, X.; Dinsmore, C. M.; Glenn, A. G.; Guastella, J.; Huang, Jin-Cheng; Ilyin, V.; Lu, Y. 1,4-Dihydroquinoxaline-2,3-diones: Antagonists of N-methyl-D-aspartate (NMDA) Receptor Glycine Site and Non-NMDA Glutamate Receptor. J. Med. Chem. 1995, 38, 4367-4379.
48. (b) Woodward, R. M.; Huettner, J. E.; Guastella, J.; Keana, J. F. W.; Weber, E. In vitro Pharmacology of ACEA-1021 and ACEA-1031: Sistemically Active Quinoxalidines with High Affinity and Selectivity for the N-methyl-D-aspartate Receptor Glycine Site. mol. Pharmacol. 1995, 47, 568-581.
49. Valko, K.; Bevan, C.; Reynolds, D. Chromatographic Hydrophobicity Index by Fast-Gradient RP-HPLC: A high-Throughput Alternative to LogP/LogD. Anal. Chem. 1997, 11, 6669.
50. Di Fabio, R.; Conti, N.; De Magistris, E.; Feriani, A. WO 9627588 A1.
51. Munson, P. D.; Rodbard, D. LIGAND: A Versatile Computerized Approach for Characterization of Ligand-binding Data. Anal. Biochem. 1980, 107, 220-239.